Clinical trial registry record

Evaluation of IBI302 Injection in nAMD or DME

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Suspended. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Suspended.
Evidence
Registered phase 1, phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated July 27, 2023.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT05961007
Last registry update
July 27, 2023
Status
Suspended
Phase
Phase 1, Phase 2
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Enrollment
234
Countries
China
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Suspended. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1, Phase 2
Study design
RANDOMIZED · SEQUENTIAL · TREATMENT · DOUBLE
Evidence population
Human clinical study registration
Participants
234
Population
ALL · 18 Years
Duration
2021-11-18 to 2024-04-30
Intervention
Intravitreal injection of IBI302(dose 1); Intravitreal injection of IBI302(dose 2); Intravitreal injection of IBI302(dose 3); Intravitreal injection of Aflibercept
Comparator
Aflibercept
Outcomes measured
Incidence and severity of ocular and non-ocular adverse events. — Up to week 20; DLT in each group — 7 days; Change of BCVA from baseline by visit — through study completion，an average of 20 weeks; Change of CST from baseline by visit — through study completion，an average of 20 weeks; Area under the concentration time curve (AUC) and Maximum plasma concentration (Cmax) — through study completion，an ave…; The ADA and neutralizing antibody — through study completion，an average of 20 weeks
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1, Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Abstract supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON